The most consistent candidate drug treatments for invasive melanoma were glucocorticoid receptor (NR3C1) agonists, AXL inhibitors, PARP1 inhibitors and HDAC inhibitors, as target gene expression for drug families predicted to target invasive melanoma. The gene discussed is AXL; the disease is melanoma.